In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicit...
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today th...
Fapon Biotech is a global leader in the In-vitro Diagnostics (IVD) industry, with a steadfast commitment to advancing global health by providing in...
Agilent Technologies Inc., announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatogra...
MasterControl, a leading provider of quality management and manufacturing software solutions, today announced the appointment of Kelly Starman as Chief M...
The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been honored for industry leadership in digital ...
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) fo...
Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs ...
Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high u...
Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Curon Biopharmaceutical (Curon), a privately held biotechnology company, &nb...
Hypoparathyroidism is a rare endocrine disease with multi-organ impacts affecting an estimated 70,000 to 90,000 people in the United States Ascendi...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the Phase 3 KeyVibe-008 trial based on th...
© 2025 Biopharma Boardroom. All Rights Reserved.
